Patients with inflammatory bowel diseases (IBDs) are at an increased risk of pancreatitis; however, the role of IBD therapy in the development of pancreatitis is currently unclear.

Data captured in a global safety database were queried to identify risk factors for developing pancreatitis among patients treated with vedolizumab, a gut-selective anti–lymphocyte trafficking agent.

Risk factors associated with serious pancreatitis included age, indication of use, use of concomitant medications, pancreatitis history, and comorbid conditions. Such findings help to inform which patients treated for IBD might have an elevated risk of developing pancreatitis, regardless of treatment.